News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioTime (BTX) Subsidiary Asterias Biotherapeutics Announces Investment By CEO


6/17/2014 10:16:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALAMEDA, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) today announced that on June 12, 2014, Pedro Lichtinger, President and Chief Executive Officer of its subsidiary Asterias Biotherapeutics, Inc. (“Asterias”) purchased from Asterias 200,000 shares of Asterias Series B common stock at a price of $2.34 per share. The funds raised by this purchase will be used in part to finance Asterias’ therapeutic product development programs, which are based on the potential of using human embryonic stem (hES) cells to create innovative new therapies for diseases and conditions for which effective treatments are not presently available.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES